Optimising personalised melanoma care: A national e-Delphi consensus survey exploring expert perspectives on the use of a novel prognostic biomarker for early-stage cutaneous malignant melanoma
{{output}}
Background: Cutaneous malignant melanoma (cMM) incidence continues to rise. AJCC staging provides broad prognostic estimates, potentially leading to overtreatment in early-stage disease. AMBLor™ is a validated IHC-based biomarke... ...
